

Listing of Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Previously Presented) A therapeutic system for oral administration of one or more active ingredients in the form of a tablet, said tablet comprising a nucleus containing the active ingredient(s) completely coated by a film of polymeric material, insoluble in and impermeable to aqueous fluids, on which have been made one or more incisions which define an area of predetermined dimensions and shape as a function of desired rate and progress of release of the active ingredient(s), said release taking place from the area of the nucleus underlying the surfaces of the film coating delimited by the incision(s), said incision(s)-delimited film coating being present before contact with aqueous fluids and being removed when the therapeutic system comes into contact with aqueous fluids.
2. (Previously Presented) The therapeutic system according to claim 1, wherein the nucleus comprises one or more polymeric substances to modulate the release of the active ingredient(s).
3. (Previously Presented) The therapeutic system according to claim 2, wherein said polymeric substances comprise between 1% and 90% in weight of said nucleus.
4. (Previously Presented) The therapeutic system according to claim 3, wherein said polymeric substances comprise between 5% and 50% in weight of said nucleus.
5. (Previously Presented) The therapeutic system according to claim 1, wherein the nucleus further comprises one or more disaggregating agents, super disaggregating agents, or a combination thereof.
6. (Previously Presented) The therapeutic system according to claim 1, wherein the nucleus further comprises one or more effervescent mixtures.

7. (Previously Presented) The therapeutic system according to claim 1, wherein the nucleus further comprises hydrophilic diluents, wetting agents, or a combination thereof.
8. (Previously Presented) The therapeutic system according to claim 1, wherein the nucleus further comprises hydrophobic diluents.
9. (Previously Presented) The therapeutic system according to claim 1, wherein the nucleus further comprises one or more substances selected from binding agents, lubricants, buffers, anti-adherents, glidants, or plasticisers.
10. (Previously Presented) The therapeutic system according to claim 1, wherein the insoluble film coating comprises one or more plasticizing substances.
11. (Previously Presented) The therapeutic system according to claim 1, wherein the insoluble film coating comprises from 0.2% to 30% of the total weight of the tablet.
12. (Previously Presented) The therapeutic system according to claim 11, wherein the insoluble film coating comprises from 2% to 25% of the total weight of the tablet.
13. (Previously Presented) The therapeutic system according to claim 1, wherein the incision(s) define an area of dimensions comprised of between 2% and 80% of the total surface of the film coating.
14. (Previously Presented) The therapeutic system according to claim 13, wherein the incision(s) define an area of dimensions comprised of between 5% and 70% of the total surface of the film coating.
15. (Previously Presented) The therapeutic system according to claim 1, wherein the insoluble film coating comprises a second film of gastroresistant and enterosoluble polymeric coating applied thereon.
16. (Previously Presented) A process of making the therapeutic system according to claim 1, comprising creating the incision(s) in the film coating with a laser.

Conte et al.
USPN: 10/507,345

17. (Previously Presented) The process according to claim 16, wherein the incision(s) in the film coating are created with a CO₂ laser device having a power of 20 W.